DEAR DR. ROACH: I am an 80-year-old female and a 25-year survivor of ovarian cancer. In the past three years, I have also had Merkel cell cancer, breast cancer, and now squamous cell cancer on my lip.

Dawn L. Hershman, MD, MS, will present work at SABCS 2023 that uses baseline sociodemographic and financial measures to predict which patients prescribed long-term therapy with aromatase inhibitors ...

Treatment with an aromatase inhibitor improves outcomes at 10 years compared to treatment with a SERM in HR+, HER2+ early breast cancer.

Boston, MA, and San Francisco, CA - The aromatase inhibitors have revolutionized breast-cancer treatment by providing a more effective alternative to tamoxifen. However, Drs David T Felson (Boston ...

Aromatase inhibitors (AIs) represent a cornerstone in the treatment of oestrogen receptor–positive breast cancer, particularly among postmenopausal women. Although these drugs have substantially ...

The SERENA-6 trial shows a 54% reduced risk of death with camizestrant, with a median PFS of 16.6 months versus 9.2 months ...

CHICAGO, Dec 11 (Reuters) - U.S. researchers may have found a way to overcome resistance to hormone-blocking breast cancer drugs, extending the life of treatments that keep the disease in check. Sign ...

Image by the US National Institutes of Health, CC 3.0 Image by the US National Institutes of Health, CC 3.0 A powerful new drug for advanced breast cancer can be used to treat emerging resistance to ...